PMID: 375847Apr 1, 1979Paper

Treatment of rheumatoid arthritis with levamisole: long-term results and immune changes

Annals of the Rheumatic Diseases
L A RungeR H Tomar

Abstract

We treated 29 rheumatoid arthritis patients with levamisole. on the basis of a 25% improvement in any 3 of 6 measurements 95% of the patients had a favourable response within 20 weeks. However, 64% of the patients discontinued levamisole by 40 to 60 weeks because of rash or secondary treatment failures. Delayed skin reactivity to streptokinase-streptodornase increased significantly in the entire treatment group, but there was in inverse correlation between skin test enhancement and clinical response. There was no overall change in lymphocytes response to phytohaemagglutinin (PHA) after 4 and 16 weeks of treatment, but seven patients with enhanced lymphocyte responsiveness to PHA experienced an earlier clinical response to levamisole. Treatment with levamisole frequently results in clinical improvement in rheumatoid arthritis, but this is not clearly related to a stimulatory effect on cell-mediated immunity. Its long-term usefulness may be limited by a high incidence of relapse and rash.

References

Jun 1, 1976·The Journal of Pharmacy and Pharmacology·A J CollinsH Worsell
Feb 21, 1976·Lancet·E C HuskissonD A Willoughby
Apr 23, 1977·Lancet·M RosenthalE Veys
Nov 1, 1977·Arthritis and Rheumatism·L A RungeR H Tomar
Feb 1, 1977·Annals of the Rheumatic Diseases·A A AndrianakosJ Duffy
Sep 1, 1976·Agents and Actions·P A DieppeE Arrigoni-Martelli
Nov 1, 1976·Clinical Immunology and Immunopathology·M E Schmidt, S D Douglas
Jun 13, 1975·Annals of the New York Academy of Sciences·C M PearsonH I Machleder
May 1, 1976·Arthritis and Rheumatism·H A SilvermanJ C McGlamory
May 1, 1970·Annals of the Rheumatic Diseases·E J DenmanR B Heath
Sep 1, 1974·Arthritis and Rheumatism·E M Lance, S C Knight
Jan 1, 1973·Pathology·H HinterbergerC Sholtz
Jan 1, 1973·Arthritis and Rheumatism·J E CurtisE M Hersh
Nov 1, 1972·Annals of the Rheumatic Diseases·S P Liyanage, H L Currey
May 1, 1973·Annals of the Rheumatic Diseases·J S StrongC J Smyth
Nov 1, 1970·Arthritis and Rheumatism·F P AlepaA J Sliwinski
Nov 1, 1968·Annals of the Rheumatic Diseases·J D Jessop, H L Currey

❮ Previous
Next ❯

Citations

Dec 1, 1986·Immunopharmacology·K KobayashiY Shiokawa
Jan 1, 1988·International Journal of Immunopharmacology·V Ruszala-MallonB S Wang
Apr 28, 2004·American Journal of Clinical Dermatology·Noah ScheinfeldJeffrey M Weinberg
Feb 21, 2014·Dermatologic Therapy·Meng-Hsuan TsaiYu-Ping Hsiao
Oct 31, 1983·The American Journal of Medicine·R S Pinals
Jul 1, 1993·Stem Cells·F MandelliG Meloni

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.